Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Boyd

Psychiatry Memphis, TN Medical Doctor

NPI 1891798989 CMS profile 131480

1715 Aaron Brenner Dr, Ste 326, Memphis, TN 38120

Open in the dashboard

General payments

$68,871

101 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Daniel Boyd of Memphis, TN is reported in the CMS Open Payments database as having received $68,871 across 101 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $28 1
2023 General $15 1
2020 General $21,901 28
2019 General $46,926 71

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Boyd
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Daniel Boyd were reported at $28. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Daniel Boyd Psychiatry median Middle half National median
2019 $46,926 $184 $59–$605 $163
2020 $21,901 $119 $36–$372 $114
2021 $0 $143 $43–$576 $132
2022 $0 $153 $50–$590 $149
2023 $15 $170 $56–$651 $160
2024 $0 $179 $57–$673 $164
2025 $28 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alkermes, Inc. $29,190 32 payments
  2. Neurocrine Biosciences, Inc. $28,995 39 payments
  3. Janssen Pharmaceuticals, Inc $5,743 14 payments
  4. Otsuka America Pharmaceutical, Inc. $3,830 12 payments
  5. Sunovion Pharmaceuticals Inc. $1,069 2 payments
  6. Teva Pharmaceuticals USA, Inc. $28 1 payment
  7. Neuronetics, Inc. $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $61,516 33 payments
  2. Travel and Lodging $3,749 33 payments
  3. Consulting Fee $2,016 1 payment
  4. Food and Beverage $1,590 34 payments
Products named General payments · program years 2019–2025
  1. ARISTADA INITIO $29,190 32 payments
  2. ARISTADA Cns $29,190 32 payments
  3. ARISTADA Cns $29,190 32 payments
  4. ARISTADA Cns $29,190 32 payments
  5. ARISTADA Cns $29,190 32 payments
  6. INGREZZA $28,995 39 payments
  7. SPRAVATO $5,743 14 payments
  8. ABILIFY MAINTENA $3,830 12 payments
  9. LATUDA $1,069 2 payments
  10. UZEDY $28 1 payment
  11. Other $15 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

430

Median for Psychiatry: 574

Drug cost

$5,046

Median for Psychiatry: $27,624

Branded share of claims

6.5%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Divalproex Sodium Er Divalproex Sodium Brand 28 $1,139
Quetiapine Fumarate Generic 38 $531
Olanzapine Generic 20 $436
Memantine Hcl Generic 26 $259
Atorvastatin Calcium Generic 26 $239
Divalproex Sodium Generic 11 $234
Trazodone Hcl Generic 34 $213
Pantoprazole Sodium Generic 16 $195
Risperidone Generic 16 $187
Losartan Potassium Generic 22 $171

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$23,936

Medicare's payments for the services billed

Medicare patients

47

Average age 62

Services billed

559

23 women, 24 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 70%
Arthritis 51%
Alzheimer's or dementia 32%
Diabetes 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

101 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record